• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
Harvard Law School Bankruptcy Roundtable

Harvard Law School Bankruptcy Roundtable

  • Blog
  • About Us
  • Coverage-in-Depth
    • Crypto-Bankruptcy
    • Purdue Pharma Bankruptcy
    • Texas Two-Step and the Future of Mass Tort Bankruptcy
  • Subscribe
  • Show Search
Hide Search

Opting into opting out: Due process and opt-out releases

By Marshall S. Huebner and Kate Somers (Davis Polk & Wardwell, LLP)

Marshall S. Huebner and Kate Somers

Since the U.S. Supreme Court issued its ruling barring nonconsensual releases in Harrington v. Purdue Pharma L.P., 144 S. Ct. 2071 (2024), there has been an even greater focus on other types of releases with respect to third parties, including both opt-out and opt-in releases. Provided that factors are satisfied, opt-out releases (which are a mechanic on a ballot or notice of nonvoting status that allows claimants to check a box to opt out of nondebtor releases in a reorganization plan) will likely be the best available pathway for effectuating the will of – and providing the best available recovery to – creditors and victims.  In Opting into opting out: Due process and opt-out releases, Davis Polk partner and Restructuring practice co-head Marshall Huebner and associate Kate Somers explore these factors and discuss the analogy between non-debtor releases in bankruptcy and Rule 23(b)(3) class actions, concluding that due process is far better served where – in appropriate cases – statutory fiduciaries overseen by courts can opt in to opt-outs, and opt out of using opt-ins.

This article was originally published in the August 2024 issue of the ABI Journal, produced by the American Bankruptcy Institute (www.abi.org). It is reprinted with the permission of the publisher.

Click here to read the full article.

Written by:
Editor
Published on:
November 19, 2024

Categories: Chapter 11, Mass Torts, Purdue Pharma Bankruptcy, Supreme CourtTags: Bankruptcy, Bankruptcy Courts, Chapter 11, Harrington v. Purdue Pharma, Kate Somers, Marshall Huebner, Marshall S. Huebner, Mass Torts, Purdue Pharma, Purdue Pharma bankruptcy, restructuring, Supreme Court, syndicated

Primary Sidebar

Categories

Recent Posts

  • Chapter 15 Case Demonstrates Its Effectiveness as an Expedient Judicial Solution for Singaporean Insolvencies in the United States May 13, 2025
  • Do Rights Offerings Reduce Bargaining Complexity in Chapter 11? May 6, 2025
  • Rockville Centre Case Offers a Framework for Settling Mass Tort Bankruptcy Claims Post-Purdue April 29, 2025

View by Subject Matter

363 sales Anthony Casey Bankruptcy Bankruptcy administration Bankruptcy Courts Bankruptcy Reform Chapter 11 Chapter 15 Claims Trading Cleary Gottlieb Comparative Law Corporate Governance COVID-19 cramdown David Skeel Derivatives DIP Financing Empirical FIBA Financial Crisis fraudulent transfer Jared A. Ellias Jevic Johnson & Johnson Jones Day Mark G. Douglas Mark Roe plan confirmation Priority Purdue Pharma Purdue Pharma bankruptcy restructuring Safe Harbors Schulte Roth & Zabel Sovereign Debt SPOE Stephen Lubben Structured Dismissals Supreme Court syndicated Texas Two-Step Trust Indenture Act Valuation Weil Gotshal Workouts

Footer

Harvard Law School Bankruptcy Roundtable

1563 Massachusetts Ave,
Cambridge, MA 02138
Accessibility | Digital Accessibility | Harvard Law School

Copyright © 2023 The President and Fellows of Harvard College

Copyright © 2025 · Navigation Pro on Genesis Framework · WordPress · Log in